<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515541</url>
  </required_header>
  <id_info>
    <org_study_id>07-1068</org_study_id>
    <nct_id>NCT00515541</nct_id>
  </id_info>
  <brief_title>Lovaza's Effect on the Activation of Platelets</brief_title>
  <acronym>LEAP</acronym>
  <official_title>Effect of the Omega n3 Fatty on Human Platelet Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invitrox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Reliant Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Invitrox</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the effects of Lovaza in platelet function studies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease remains a leading cause of death in North America (1). Uncontrolled
      platelet activation, adhesion and aggregation initiated by vessel wall plaque rupture are
      thought to be responsible for acute vascular occlusion in many situations (2-5). Although
      many platelet inhibition drugs are available, all currently available drugs have undesirable
      toxicity profiles (6-8). Thus, reduction in toxicity and improved management of patients with
      thrombotic diseases remains an unmet medical need.

      Platelet activation plays a pivotal role in the pathogenesis of acute coronary syndromes,
      strokes and other thrombophilic diseases. Atheromatous plaque rupture changes the shear
      forces of blood flowing over the injured vessel surface and also exposes collagen as well as
      other prothrombotic factors (9-11). As the initial hemostatic event, platelets become
      activated and cover the injured surface. Following platelet activation highly active
      substances like adenosine diphosphate (ADP) and thromboxane A2 (TxA2) are released from the
      platelet to promote and recruit further platelet aggregation to the injury site (12). If this
      process proceeds unabated, as it often does in atherosclerotic diseases, the vessel becomes
      occluded and infarction may follow.

      Lovaza® (Reliant Pharmaceutical Inc., Liberty Corner, NJ), a commercially available
      formulation that contains 90 % omega-3-acid ethyl esters (46% eicosapentaenoic acid -EPA- and
      38% docosohexaenoic acid -DHA-), has the potential ability to modify the recruitment of
      additional platelets to the growing thrombus by promoting synthesis of thromboxane A3 (TxA3),
      a poor platelet activator, instead of thromboxane A2, a potent platelet activator. Agents
      used to inhibit platelet function such as aspirin and clopidogrel are not always effective
      (13-16). Unfortunately, some patients do not respond to these therapeutics (17-24). Realistic
      numbers for patient resistance to these drugs are probably 10-15% for ASA and 20-30% for
      clopidogrel. Almost all resistant patients have less favorable outcomes and are unaware of
      this potentially life-threatening problem until a severe cardiac adverse event occurs.
      Lovaza® may add additional therapeutic benefit to these patients.(25,26) Beyond the
      occasional patient with complaints of eructation or a &quot;fishy&quot; taste in their mouth, Lovaza®
      has a benign toxicity profile. If Lovaza® can be shown to have a clinically relevant
      anti-platelet effect, it may have a use to either replace or reduce the dose of more toxic
      anti-platelet agents.

      The proposed biochemical mechanism for the anti-platelet effect of omega n3 fatty acids is
      based on modifications in platelet prostaglandin metabolism (27-31). Cellular membranes are
      primarily composed of phospholipids (PL). The backbone of PL's is glycerol. The glycerol
      hydroxyl groups in position 1 and 2 bind two fatty acid molecules through formation of ester
      bonds (31). The third hydroxyl binds the so-called head group, which may be choline,
      inositol, ethanolamine or serine. At least in the case of platelets the fatty acid at the C-2
      position is often the unsaturated arachidonic fatty acid (an omega n6 fatty acid). When
      Lovaza® is ingested (an omega n3 fatty acid), the unsaturated fatty acid at the C2 position
      can be DHA or EPA. Several important differences result from this substitution including an
      important effect on platelet function. As part of the platelet activation process,
      phospholipase A2 clips the fatty acid at the C-2 position, either arachidonic acid or DHA/EPA
      (31). In the case of the platelet, the fatty acid is then metabolized through an enzyme
      called COX-1 to a thromboxane (32-35). When the fatty acid is arachidonic acid, thromboxane
      A2 is synthesized (TxA2). TxA2 is a very potent platelet activator and vasoconstrictor. In
      the case of DHA or EPA, a series 3 TxA3 is synthesized, a poor platelet activator and
      vasoconstrictor (32-35). Production of TxA3 underlies the potential anti-platelet effect of
      Lovaza®.

      The second effect of DHA inclusion in PL's is a newly discovered alteration in the cell
      membrane structure. It is now well established that DHA promotes &quot;lipid raft&quot; formation in
      cellular membranes (36-38). These rafts, primarily composed of sphingomyelin and cholesterol,
      form the sites where some transmembrane proteins can be inserted into the membrane. These
      transmembrane proteins may be sites for ion channels or receptors that define important
      cellular functions and can be a means to activate cells. Thus, DHA's ability to promote raft
      formation may have a profound beneficial effect on platelet function.

      Since it is the Lovaza®-alteration of the platelet membrane that leads to its clinical
      benefit, assays to determine how the lipid composition of the platelet membrane changes after
      ingestion of Lovaza® will be carried out. The concept of these experiments is fairly simple.
      A standard well-established 1H NMR method will be used to detect changes in the lipid
      composition of the platelet membrane as a function of the Lovaza® dose (39-41). From these
      experiments we will be able to prove that DHA or EPA from Lovaza® is actually directly
      incorporated into a platelet membrane
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Aggegation (Arachiodonic Acid)Using a PAP-8E (BioData Corp.)</measure>
    <time_frame>up to and including closeout at 24 weeks</time_frame>
    <description>The PAP-8E measures platelet aggregation in platelet rich plasma (PRP). Platelet responses to a series of common agonists cause changes in optical density that are measured. The instrument is blanked (100% baseline (optimal transmission)) by inserting a platelet poor plasma (PPP) specimen into the appropriate channel. The PRP is then inserted into the same well. The difference in optical density between the PPP and the PRP 0% baseline (optical transmission) is recorded for several minutes when the agonist reagent is added to the PRP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding Time</measure>
    <time_frame>up to and including closeout at 24 weeks</time_frame>
    <description>Bleeding time is a measure of how well platelets interact with blood vessel walls to form a clot. A manual blood pressure cuff is placed 2 inches above the antecubital fossa and inflated to 40mmHg. Using a standard Surgicutt device, a small incision is made and a stopwatch is started. The incision edge is blotted at 30 second intervals with standard filter paper until the bleeding has stopped. The time to hemostasis is noted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EQELS (Electrophoretic Quasi Elastic Light Scattering: Change in Mobility After the Addition of Arachidonic Acid</measure>
    <time_frame>up to and including closeout at 24 weeks</time_frame>
    <description>Measurements were made using a modified device (EQELS) to specifications of constant current, high electric field and a scattering angle of 30 degrees. EQELS provides a sensitive assessment of subtle changes in the cell surface that occurs with activation, ligand binding or apoptosis. These changes are the result of different distributions of charged groups that define a surface charge finger print for the current state of activation of the cell. Resting state platelets have a negative surface charge, whereas fully activated platelets have a positive surface charge.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Occurence of Any Type of Bleeding</measure>
    <time_frame>up to and including closeout at 24 weeks</time_frame>
    <description>was there any bleeding occurance during the accessed interval</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient is not on Aspirin, Clopidogrel, or Warfarin and is taking escalating doses of study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient is on regular dose of Aspirin ( &lt; or = 325mg). Patient is not taking Clopidogrel or Warfarin and is taking the escalating doses of Lovaza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient is taking regularly 75mg of clopidogrel daily and Aspirin (&lt; or = 325mg) and not taking Warfarin and is taking the escalating doses of Lovaza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient is regularly taking Warfarin daily and Aspirin (&lt; or = 325mg)and is not taking Clopidogrel and is taking the escalating doses of Lovaza</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females older than 18 years old who are able to ingest omega n3 fatty acids
             are eligible for this trial and are:

          -  On no antiplatelet and anticoagulation therapy, OR

          -  On chronic therapy with warfarin or aspirin alone (&lt; or =325 mg/day)or combination
             therapy with clopidogrel and aspirin (&lt; or =325 mg/day).

          -  The subject must be able to read, understand, and sign an informed consent form and
             follow protocol.

          -  To be enrolled in the study, subjects must be clinically stable on stable medical
             therapy throughout the duration of the study and meet the following criteria:

          -  Healthy volunteers

          -  Volunteers with stable coronary artery disease are those with:

          -  Prior MI (&gt;1 month) OR

          -  Prior revascularization: angioplasty ± stenting (&gt; 1 month) OR

          -  Coronary artery bypass grafting (&gt;3 months) OR

          -  Documented disease on coronary angiography.

          -  No planned no planned procedures or changes in medical therapies over the 24-week
             duration of the study

          -  Volunteers with stable atrial fibrillation are those with:

          -  Rate-controlled or paroxysmal atrial fibrillation on stable antiarrhythmic therapy.

          -  On a stable dose of warfarin and regular follow-up in an anticoagulation (&quot;coumadin&quot;)
             clinic.

          -  No planned changes in antiarrhythmic therapies or cardioversion during the duration of
             the study.

          -  No recent admissions for atrial fibrillation (&gt; 3 months)

          -  Subjects may not ingest other drugs known to cause a significant platelet abnormality
             while participating in this trial. (See list of prohibited medications, as outlined in
             Section 9)

          -  Patients must be assessable to the investigator for scheduled clinic visits during the
             duration of the trial.

          -  All female subjects of child bearing potential must have a negative serum pregnancy
             test prior to randomization and not plan on getting pregnant for the duration of the
             study.

        Exclusion Criteria:

          -  Any medical condition that would preclude ingestion of omega n3 fatty acids (Lovaza®).

          -  Subjects taking nutritional supplements of fish oil or flaxseed oil. These patients
             may become eligible if they are willing to discontinue these nutritional supplements
             for a 2-week washout period.

          -  Any other medical condition that would adversely affect the study objectives.

          -  Chronic medical conditions known to be associated with abnormal platelet function
             including:

          -  Liver dysfunction including abnormal liver function tests (AST, ALT, or alkaline
             phosphatase &gt; upper limit of normal), known cirrhosis or chronic hepatitis.

          -  Chronic kidney disease with a calculated creatinine clearance &lt; 60 ml/min (MDRD)
             and/or a serum creatinine &gt; 2.0 mg/dl.

          -  History of significant anemia, or baseline hemoglobin &lt; 11.0 g/dl.

          -  Baseline PT&gt;ULN, INR&gt;1.3, and aPTT&gt;ULN in subjects who are not on chronic warfarin
             therapy.

          -  History of thrombocytopenia, or baseline platelet count of &lt; 100,000

          -  History of thrombocytosis, or baseline platelet count of &gt; 600,000

          -  Known bleeding diathesis and/or congenital hemostasis disorder and/or congenital
             platelet abnormalities.

          -  Any history of stroke in the past 12 months.

          -  History of peptic ulcer disease in the past year or gastrointestinal bleeding in the
             last 3 months.

          -  Genitourinary bleeding in the last 3 months.

          -  HIV or other infectious diseases that would expose laboratory personnel to
             unacceptable risks.

          -  Treatment within 30 days with an antiplatelet agent other than aspirin or clopidogrel
             such as eptifibatide, tirofiban or abciximab.

          -  Treatment within the past 7 days with unfractionated or low-molecular- weight heparin.

          -  Allergy to iodine, fish, or other components of the study drug.

          -  Alcohol or substance abuse.

          -  Emotionally or psychiatrically unstable.

          -  Use of any investigational drug or device within the past 30 days

          -  Any other factor that the investigator feels would put the patient at increased risk
             if participating in the study.

          -  Any Terminal illness or illness that may cause mortality that could obscure the
             results of the test in any way for them to appear inaccurate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricio Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Cohen MG, Rossi JS, Garbarino J, Bowling R, Motsinger-Reif AA, Schuler C, Dupont AG, Gabriel D. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel. Thromb Res. 2011 Oct;128(4):335-40. doi: 10.1016/j.thromres.2011.04.023. Epub 2011 May 28.</citation>
    <PMID>21621252</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2007</study_first_submitted>
  <study_first_submitted_qc>August 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2007</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>June 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2013</results_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelet</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Lipid</keyword>
  <keyword>Fish Oil</keyword>
  <keyword>Omega 3</keyword>
  <keyword>DHA</keyword>
  <keyword>EPA</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Clotting</keyword>
  <keyword>platelet function</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Weight and Bleeding risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at the Carolina Center for Clinical Trials at the University of North Carolina at Chapel Hill campus. Enrollment period: 9/24/07 through 10/13/08.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A: Subjects on Lovaza Only</title>
          <description>Group A: Subject is healthly and not on Aspirin, Clopidogrel, or Warfarin. Subjects will be taking escalating doses of the study drug (Lovaza)up to 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Group B: Subjects on Lovaza Plus Aspirin</title>
          <description>Group B: Subject is only taking Aspirin (&lt; or = 325mg) daily. Subjects will be taking escalating doses of study drug (Lovaza) in addition to aspirin up to 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Group C: Subjects on Lovaza Plus Clopidogrel and Aspirin</title>
          <description>Subject is regularly taking Clopidogrel (75mg)and Aspirin (&lt; or = 325mg)daily, and not taking Warfarin. Subjects will be taking escalating doses of study drug (Lovaza)in addition to Clopidogrel and Aspirin up to 24 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Group D: Subjects on Lovaza Plus Warfarin and Aspirin</title>
          <description>Subject is regularly taking Warfarin and Aspirin (&lt; or = 325mg)daily, and not taking Clopidogrel. Subjects will be taking escalating doses of study drug (Lovaza)in addition to Warfarin and Aspirin up to 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Weeks (1 gm Lovaza)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10">One subject pulled after baseline. One subject pulled due to no show for appt.after baseline</participants>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10">One subject pulled due to no show for appt. after baseline.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>12 Weeks (2 gm Lovaza)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>18 Weeks (4 gm Lovaza)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9">One subject withdrew at 12 weeks due to acquired bleeding disorder present before enrolling.</participants>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="9">One subject withdrew at 14 weeks with GI problems.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>24 Weeks (8 gm Lovaza)</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7">Two subjects withdrew at 20 and 21 weeks due to nausea. Subjects were closed out early.</participants>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6">Three subjects withdrew after 18 weeks (1 GI problem, 1 undefined medical problem, 1 no show)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10">All subjects completed 24 weeks.</participants>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="10">All subjects completed 24 weeks.</participants>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No show for appointments</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The number of subjects for baseline does not represent the number of subjects that completed the 24 week study.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A: Subject on Lovaza Only</title>
          <description>Group A: Subject is not on Aspirin, Clopidogrel, or Warfarin. Subject is taking escalating doses of study drug (Lovaza)over a 24 week period.</description>
        </group>
        <group group_id="B2">
          <title>Group. B: Subject on Lovaza + Aspirin</title>
          <description>Group B: Subject on Aspirin (&lt; or = 325mg and is not taking Clopidogrel or Warfarin. Subject is taking escalating doses of Lovaza over a 24 week period.</description>
        </group>
        <group group_id="B3">
          <title>Group C: Subject on Lovaza + Clopidogrel + Aspirin</title>
          <description>Group C: Subject is taking Clopidogrel 75mg)and Aspirin (&lt; or = 325mg) and not taking Warfarin. Subject is taking escalating doses of Lovaza over a 24 week period.</description>
        </group>
        <group group_id="B4">
          <title>Group D: Subject on Lovaza + Warfarin + Aspirin</title>
          <description>Group D: Subject is taking Warfarin and Aspirin (&lt; or = 325mg)and is not taking Clopidogrel. Subject is taking escalating doses of Lovaza over a 24 week period.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="11"/>
            <count group_id="B5" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="NA">The reporting site did not supply this information to Invitrox. We have requested information but have been informed that it is not available.Group D was not included in final report.</measurement>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="NA">The reporting site did not supply this information to Invitrox. We have requested information but have been informed that it is not available.Group D was not included in final report.</measurement>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Aggegation (Arachiodonic Acid)Using a PAP-8E (BioData Corp.)</title>
        <description>The PAP-8E measures platelet aggregation in platelet rich plasma (PRP). Platelet responses to a series of common agonists cause changes in optical density that are measured. The instrument is blanked (100% baseline (optimal transmission)) by inserting a platelet poor plasma (PPP) specimen into the appropriate channel. The PRP is then inserted into the same well. The difference in optical density between the PPP and the PRP 0% baseline (optical transmission) is recorded for several minutes when the agonist reagent is added to the PRP.</description>
        <time_frame>up to and including closeout at 24 weeks</time_frame>
        <population>Based on number of subjects completing 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Subject on Lovaza Only</title>
            <description>Group A: Subject on study drug (Lovaza) and not on Aspirin, Clopidogrel, or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Subject on Lovaza + Aspirin</title>
            <description>Group B: Subject on study drug (Lovaza) plus Aspirin (&lt; or = 35mg)and not on Clopidogrel or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O3">
            <title>Group C: Subject on Lovaza + Clopidogrel + Aspirin</title>
            <description>Group C: Subject on study drug (Lovaza) plus Clopidogrel (75mg) and Aspirin (&lt; or = 325mg, and not on Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O4">
            <title>Group D: Subject on Lovaza + Warfarin + Aspirin</title>
            <description>Group D: Subject on study drug (Lovaza) plus Warfarin and Aspirin (&lt; or = 325mg, and not on Clopidogrel. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Aggegation (Arachiodonic Acid)Using a PAP-8E (BioData Corp.)</title>
          <description>The PAP-8E measures platelet aggregation in platelet rich plasma (PRP). Platelet responses to a series of common agonists cause changes in optical density that are measured. The instrument is blanked (100% baseline (optimal transmission)) by inserting a platelet poor plasma (PPP) specimen into the appropriate channel. The PRP is then inserted into the same well. The difference in optical density between the PPP and the PRP 0% baseline (optical transmission) is recorded for several minutes when the agonist reagent is added to the PRP.</description>
          <population>Based on number of subjects completing 24 weeks</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="36" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="49"/>
                    <measurement group_id="O3" value="5.5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="O4" value="8" lower_limit="2" upper_limit="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 gram Lovaza Daily (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="73" upper_limit="100"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O3" value="6.5" lower_limit="2" upper_limit="15"/>
                    <measurement group_id="O4" value="9" lower_limit="3" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 grams Lovaza Daily (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="35" upper_limit="93"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O3" value="6" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O4" value="12" lower_limit="7" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 grams Lovaza Daily (Week 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="47" upper_limit="82"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="8"/>
                    <measurement group_id="O4" value="10" lower_limit="6" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 grams Lovaza Daily (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="80" upper_limit="85"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="85"/>
                    <measurement group_id="O3" value="5" lower_limit="1" upper_limit="14"/>
                    <measurement group_id="O4" value="22" lower_limit="14" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Occurence of Any Type of Bleeding</title>
        <description>was there any bleeding occurance during the accessed interval</description>
        <time_frame>up to and including closeout at 24 weeks</time_frame>
        <population>Subjects would indicate if they had any bleeding episode during the trial at each of their testing intervals</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Subject on Lovaza Only</title>
            <description>Group A: Subject on study drug (Lovaza) and not on Aspirin, Clopidogrel, or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Subject on Lovaza + Aspirin</title>
            <description>Group B: Subject on study drug (Lovaza) plus Aspirin (&lt; or = 35mg)and not on Clopidogrel or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O3">
            <title>Group C: Subject on Lovaza + Clopidogrel + Aspirin</title>
            <description>Group C: Subject on study drug (Lovaza) plus Clopidogrel (75mg) and Aspirin (&lt; or = 325mg, and not on Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O4">
            <title>Group D: Subject on Lovaza + Warfarin + Aspirin</title>
            <description>Group D: Subject on study drug (Lovaza) plus Warfarin and Aspirin (&lt; or = 325mg, and not on Clopidogrel. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>The Occurence of Any Type of Bleeding</title>
          <description>was there any bleeding occurance during the accessed interval</description>
          <population>Subjects would indicate if they had any bleeding episode during the trial at each of their testing intervals</population>
          <units>Number of occurance</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Time</title>
        <description>Bleeding time is a measure of how well platelets interact with blood vessel walls to form a clot. A manual blood pressure cuff is placed 2 inches above the antecubital fossa and inflated to 40mmHg. Using a standard Surgicutt device, a small incision is made and a stopwatch is started. The incision edge is blotted at 30 second intervals with standard filter paper until the bleeding has stopped. The time to hemostasis is noted.</description>
        <time_frame>up to and including closeout at 24 weeks</time_frame>
        <population>Based on number of subjects completing 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Subject on Lovaza Only</title>
            <description>Group A: Subject on study drug (Lovaza) and not on Aspirin, Clopidogrel, or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Subject on Lovaza + Aspirin</title>
            <description>Group B: Subject on study drug (Lovaza) plus Aspirin (&lt; or = 35mg)and not on Clopidogrel or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O3">
            <title>Group C: Subject on Lovaza + Clopidogrel + Aspirin</title>
            <description>Group C: Subject on study drug (Lovaza) plus Clopidogrel (75mg) and Aspirin (&lt; or = 325mg, and not on Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O4">
            <title>Group D: Subject on Lovaza + Warfarin + Aspirin</title>
            <description>Group D: Subject on study drug (Lovaza) plus Warfarin and Aspirin (&lt; or = 325mg, and not on Clopidogrel. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Time</title>
          <description>Bleeding time is a measure of how well platelets interact with blood vessel walls to form a clot. A manual blood pressure cuff is placed 2 inches above the antecubital fossa and inflated to 40mmHg. Using a standard Surgicutt device, a small incision is made and a stopwatch is started. The incision edge is blotted at 30 second intervals with standard filter paper until the bleeding has stopped. The time to hemostasis is noted.</description>
          <population>Based on number of subjects completing 24 weeks</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150" lower_limit="120" upper_limit="180"/>
                    <measurement group_id="O2" value="240" lower_limit="210" upper_limit="330"/>
                    <measurement group_id="O3" value="570" lower_limit="440" upper_limit="720"/>
                    <measurement group_id="O4" value="240" lower_limit="195" upper_limit="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 gram Lovaza Daily (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" lower_limit="180" upper_limit="300"/>
                    <measurement group_id="O2" value="345" lower_limit="240" upper_limit="450"/>
                    <measurement group_id="O3" value="720" lower_limit="450" upper_limit="720"/>
                    <measurement group_id="O4" value="285" lower_limit="218" upper_limit="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 grams Lovaza Daily (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240" lower_limit="180" upper_limit="270"/>
                    <measurement group_id="O2" value="390" lower_limit="330" upper_limit="450"/>
                    <measurement group_id="O3" value="690" lower_limit="540" upper_limit="720"/>
                    <measurement group_id="O4" value="285" lower_limit="188" upper_limit="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 grams Lovaza Daily (Week 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" lower_limit="180" upper_limit="270"/>
                    <measurement group_id="O2" value="330" lower_limit="300" upper_limit="420"/>
                    <measurement group_id="O3" value="600" lower_limit="360" upper_limit="780"/>
                    <measurement group_id="O4" value="240" lower_limit="210" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 grams Lovaza Daily (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" lower_limit="210" upper_limit="300"/>
                    <measurement group_id="O2" value="360" lower_limit="330" upper_limit="420"/>
                    <measurement group_id="O3" value="600" lower_limit="60" upper_limit="720"/>
                    <measurement group_id="O4" value="270" lower_limit="195" upper_limit="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group B baseline vs. Group B Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>A P-value &lt;0.05 when compared to baseline is considered significant.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EQELS (Electrophoretic Quasi Elastic Light Scattering: Change in Mobility After the Addition of Arachidonic Acid</title>
        <description>Measurements were made using a modified device (EQELS) to specifications of constant current, high electric field and a scattering angle of 30 degrees. EQELS provides a sensitive assessment of subtle changes in the cell surface that occurs with activation, ligand binding or apoptosis. These changes are the result of different distributions of charged groups that define a surface charge finger print for the current state of activation of the cell. Resting state platelets have a negative surface charge, whereas fully activated platelets have a positive surface charge.</description>
        <time_frame>up to and including closeout at 24 weeks</time_frame>
        <population>Based on number of subjects completing 24 weeks. Change in EQELS value after the addition of Arachidonic Acid.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A: Subject on Lovaza Only</title>
            <description>Group A: Subject on study drug (Lovaza) and not on Aspirin, Clopidogrel, or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O2">
            <title>Group B: Subject on Lovaza + Aspirin</title>
            <description>Group B: Subject on study drug (Lovaza) plus Aspirin (&lt; or = 35mg)and not on Clopidogrel or Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O3">
            <title>Group C: Subject on Lovaza + Clopidogrel + Aspirin</title>
            <description>Group C: Subject on study drug (Lovaza) plus Clopidogrel (75mg) and Aspirin (&lt; or = 325mg, and not on Warfarin. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
          <group group_id="O4">
            <title>Group D: Subject on Lovaza + Warfarin + Aspirin</title>
            <description>Group D: Subject on study drug (Lovaza) plus Warfarin and Aspirin (&lt; or = 325mg, and not on Clopidogrel. Subject on escalating doses of Lovaza over a 24 week period.</description>
          </group>
        </group_list>
        <measure>
          <title>EQELS (Electrophoretic Quasi Elastic Light Scattering: Change in Mobility After the Addition of Arachidonic Acid</title>
          <description>Measurements were made using a modified device (EQELS) to specifications of constant current, high electric field and a scattering angle of 30 degrees. EQELS provides a sensitive assessment of subtle changes in the cell surface that occurs with activation, ligand binding or apoptosis. These changes are the result of different distributions of charged groups that define a surface charge finger print for the current state of activation of the cell. Resting state platelets have a negative surface charge, whereas fully activated platelets have a positive surface charge.</description>
          <population>Based on number of subjects completing 24 weeks. Change in EQELS value after the addition of Arachidonic Acid.</population>
          <units>mobility units</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="-0.08" upper_limit="1.85"/>
                    <measurement group_id="O2" value="-0.04" lower_limit="-1.38" upper_limit="0.39"/>
                    <measurement group_id="O3" value="-1.04" lower_limit="-1.26" upper_limit="-0.89"/>
                    <measurement group_id="O4" value="-1.10" lower_limit="-1.19" upper_limit="-0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 gram Lovaza Daily (Week 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" lower_limit="-0.93" upper_limit="0.18"/>
                    <measurement group_id="O2" value="-0.72" lower_limit="-1.03" upper_limit="-0.37"/>
                    <measurement group_id="O3" value="-0.73" lower_limit="-1.09" upper_limit="0.56"/>
                    <measurement group_id="O4" value="-0.50" lower_limit="-0.79" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 grams Lovaza Daily (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" lower_limit="-1.11" upper_limit="-0.55"/>
                    <measurement group_id="O2" value="-1.30" lower_limit="-1.62" upper_limit="-1.17"/>
                    <measurement group_id="O3" value="-1.29" lower_limit="-1.40" upper_limit="-1.05"/>
                    <measurement group_id="O4" value="-0.58" lower_limit="-1.01" upper_limit="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 grams Lovaza Daily (Week 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" lower_limit="-1.39" upper_limit="-0.99"/>
                    <measurement group_id="O2" value="-0.94" lower_limit="-1.11" upper_limit="-0.89"/>
                    <measurement group_id="O3" value="-1.14" lower_limit="-1.29" upper_limit="-0.94"/>
                    <measurement group_id="O4" value="-0.44" lower_limit="-1.91" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 grams Lovaza Daily (Week 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" lower_limit="-1.15" upper_limit="-0.80"/>
                    <measurement group_id="O2" value="-0.97" lower_limit="-1.09" upper_limit="-0.83"/>
                    <measurement group_id="O3" value="-0.89" lower_limit="-1.31" upper_limit="-0.80"/>
                    <measurement group_id="O4" value="-0.19" lower_limit="-0.76" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The median of Groups A, B, and C grouped together was compared Baseline to Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The median of Groups A, B, and C grouped together was compared Baseline to Week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Each patient was monitored for the full time period of 24 weeks, unless withdrawn from study early.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A</title>
          <description>Lovaza only</description>
        </group>
        <group group_id="E2">
          <title>Group B</title>
          <description>Lovaza plus aspirin</description>
        </group>
        <group group_id="E3">
          <title>Group C</title>
          <description>Lovaza plus clopidogrel</description>
        </group>
        <group group_id="E4">
          <title>Group D</title>
          <description>Lovaza plus aspirin plus coumadin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Minor Bleeding</sub_title>
                <description>Subject had finger injury with minor bleeding that was a concern. The subject withdrew from study at 12 week testing interval.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Unknown medical issue</sub_title>
                <description>Subject was withdrawn from study at 18 Week testing period due to undefined medical issue.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Attributed to drug (intervention). Discontinued the study prior to Week 24 (Week 20, Week 21).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>GI problem</sub_title>
                <description>Attributed to drug (intervention). Discontinued the study prior to Week 24 (Week 14, Week 18).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Elevated liver enzymes</sub_title>
                <description>Subject was removed from study by physician.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Major limitation for this pilot study was the small number of patients analyzed per group. Despite the small numbers we were able to show the statistical significance for a change in the platelet surface charge with Lovaza.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Don A. Gabriel</name_or_title>
      <organization>Invitrox, Inc</organization>
      <phone>(919) 485-4600</phone>
      <email>dgabriel@invitrox.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

